|
DYN Dyne Therapeutics, Inc 1818794 |
| Income Statement |
|
Net Income
|
2026-03-31
|
$-120,854,000.00 |
| Balance Sheet |
|
Current Assets
|
$1,021,027,000.00 |
|
Assets
|
$1,079,950,000.00 |
|
Current Liabilities
|
$51,249,000.00 |
|
Liabilities
|
$214,895,000.00 |
|
Equity
|
$865,055,000.00 |
|
Shares Out
|
165201329.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-144,922,000.00 |
|
Investing Cash Flow
|
$-2,392,000.00 |
| Market Analysis |
Market Cap
|
$4,250,630,195.17 |
|
Price
|
$24.60 |
|
BVPS
|
5.24 |
|
PB
|
4.91 |
|
EPS
|
-0.73 |
|
FCF
|
$-145,143,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-08-01 09:31:21 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-08-03 10:01:16 |
|
| Apr |
May |
Jun |
| 2026-03-02 |
-0.76 |
|
|
2026-05-11 |
-0.73 |
|
| Jul |
Aug |
Sep |
|
|
2025-07-28 |
-0.97 |
|
|
|
| Oct |
Nov |
Dec |
|
|
|
|
2025-11-05 |
-0.76 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view DYN documents filed with the SEC.
DYN Filings
Clear
